PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Prior IV thrombolysis does not dictate first-line thrombectomy technique

alteplasetenecteplaseintravenous thrombolysismechanical thrombectomycontact aspirationstent retrieveracute ischaemic strokelarge vessel occlusionVECTOR trialsecondary analysisneurointervention Neurology / Neuropharmacology

Background Information

Does prior thrombolysis influence thrombectomy effectiveness in stroke recovery?

The impact of prior intravenous thrombolysis (IVT) on thrombectomy strategies for stroke remains uncertain, affecting clinical decision-making. In the VECTOR trial's secondary analysis, prior IVT did not significantly alter reperfusion success between thrombectomy strategies, though a slight advantage for contact aspiration (CA) was noted in non-IVT patients. Both contact aspiration and stent retriever plus contact aspiration are viable regardless of IVT use; findings are preliminary and specific to MRI-selected patients using alteplase. Prior IVT does not notably affect thrombectomy strategy outcomes, suggesting broad applicability of techniques.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Mouyal SJ, Maïer B, Labreuche J, Desilles JP, Mazighi M, Bourcier R, Redjem H

Citation: Mouyal SJ, Maïer B, Labreuche J, et al. Impact of prior intravenous thrombolysis on first-line thrombectomy strategy. A secondary analysis of the VECTOR trial. European stroke journal. 2026;11(7). doi:10.1093/esj/aakag087

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.